Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O.Box: 14395-836, Tehran, Iran.
Department of Medical Radiation Engineering, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Appl Radiat Isot. 2020 Dec;166:109396. doi: 10.1016/j.apradiso.2020.109396. Epub 2020 Aug 27.
Radiopharmaceuticals with therapeutic applications are designed to deliver high doses of radiation to target organs with minimizing unwanted radiation to healthy tissues. Owing to the potential of targeted radiotherapy to treat a wide range of malignancies, Tm -EDTMP was developed for possible therapeutic applications. This study describes absorbed dose prediction of Tm-EDTMP in human organs after animal injection which is determined via medical internal radiation dose (MIRD) and MCNP-4C code methods. It was estimated that a 1-MBq administration of Tm-EDTMP into the human body would result in an absorbed dose of 37.9 mGy (MIRD method) and 38.02 mGy (MCNP-4C code) in the bone surface after 60 days post injection. Highest and lowest difference between MIRD and MCNP results are for lung and bone surface respectively. Finally, the results show that there is a good agreement between MIRD method and MCNP-4C simulation code for absorbed dose estimation.
具有治疗应用的放射性药物旨在将高剂量的辐射递送到靶器官，同时将对健康组织的不必要辐射降至最低。由于靶向放疗有可能治疗广泛的恶性肿瘤，因此开发了 Tm-EDTMP 用于可能的治疗应用。本研究通过医学内部辐射剂量（MIRD）和 MCNP-4C 代码方法描述了动物注射后 Tm-EDTMP 在人体器官中的吸收剂量预测。据估计，在注射后 60 天，将 1MBq 的 Tm-EDTMP 注入人体将导致骨表面的吸收剂量为 37.9 mGy（MIRD 方法）和 38.02 mGy（MCNP-4C 代码）。MIRD 结果与 MCNP 结果之间的最大和最小差异分别是肺和骨表面。最后，结果表明，MIRD 方法和 MCNP-4C 模拟代码在吸收剂量估计方面具有良好的一致性。
